Complete Remission with Reduction of High-risk Clones following Haploidentical NK Cell Therapy against MDS and AML.

CONCLUSION: Overall, this study suggests that high-risk MDS is responsive to NK cell therapy and supports the use of haploidentical NK cell infusions as a bridge to HSCT in refractory patients. Objective clinical responses and reduction of high-risk clones was associated with detectable donor-derived NK cells, immunoediting of residual blast cells, and less pronounced host immune activation.
PMID: 29444931 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 14, 2018 Category: Cancer & Oncology Authors: Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikstrom KI, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ Tags: Clin Cancer Res Source Type: research